ロード中...
Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities
There are no FDA-approved drugs to mitigate the delayed effects of radiation exposure that may occur after a radiological attack or nuclear accident. To date, angiotensin-converting enzyme inhibitors are one of the most successful candidates for mitigation of hematopoietic, lung, kidney, and brain i...
保存先:
| 出版年: | Front Pharmacol |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8111401/ https://ncbi.nlm.nih.gov/pubmed/33986677 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.646076 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|